Consistent with the aims of the IRCSSA, this R01 application will examine whether noradrenergic agents, shown to be effective in improving stress-induced decrements in self-control (see Project 2: PI - Arnsten) and to attenuate stress-induced reinstatement to drug use with pre-clinical models, will attenuate the ability of stress to precipitate smoking lapse behavior in humans. Several lines of evidence identify that stress is a primary mechanism involved in smoking relapse. Despite this knowledge, targeting stress-related relapse as a viable medications development strategy for nicotine dependence has not yet been explored. For the current proposal, we are planning to continue with the development of a novel self-administration paradigm to examine how stress facilitates lapse behavior for the purpose of medication screening. The first occurrence of smoking during a cessation attempt is a critical transition, and represents an important target for medication development. Our lapse model is focused on two primary aspects of early lapse behavior: 1) ability to resist the first cigarette, representing a laboratory marker of self-control and 2) subsequent smoking. We have several ongoing studies utilizing this smoking-lapse model to examine various precipitants of relapse (stress, nicotine deprivation, food deprivation, alcohol, cigarette availability) and are currently using these models to examine effects of medications hypothesized to influence the models'primes (R21DA017234;P50AA015632;P50DA013334). Use of such laboratory-based paradigms provides a means to efficiently and cost-effectively screen new therapeutics, and to translate pre-clinical findings generated by IRCSSA Projects 2 to 5, to relapse behavior in humans. The primary aim of STUDY 1 will be to finalize the parameters of the Stress-Lapse Model, which will model the effect of stress + nicotine deprivation + cigarette availability on the inability to resist smoking in daily smokers. Secondarily, we will examine potential mechanisms underlying stress-precipitated smoking lapse behavior including self-control, craving, mood, cardiovascular reactivity, stress-related neuroendocrine measures, neuropeptides, and endocannabinoids. For STUDY 2 (Guanfacine, an alpha-2 adrenergic receptor agonist) and STUDY 3 (Carvedilol, an alpha-1 and beta adrenergic blocker), we will use the Stress- Lapse Model to examine whether noradrenergic agents attenuate the ability of stress to precipitate smoking lapse behavior, and will explore potential mechanisms for medication effects. Results will provide important evidence that targeting stress-related relapse is a viable medications development strategy for nicotine dependence, and will provide the impetus to expand this investigation to other addictive disorders.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Linked Research project Grant (RL1)
Project #
3RL1DA024857-03S1
Application #
7892089
Study Section
Special Emphasis Panel (ZRR1-SRC (99))
Program Officer
Hoffman, Allison
Project Start
2007-09-30
Project End
2010-06-30
Budget Start
2009-07-01
Budget End
2010-06-30
Support Year
3
Fiscal Year
2009
Total Cost
$82,745
Indirect Cost
Name
Yale University
Department
Psychiatry
Type
Schools of Medicine
DUNS #
043207562
City
New Haven
State
CT
Country
United States
Zip Code
06520
Verplaetse, Terril L; Weinberger, Andrea H; Ashare, Rebecca L et al. (2018) Pilot investigation of the effect of carvedilol on stress-precipitated smoking-lapse behavior. J Psychopharmacol 32:1003-1009
Verplaetse, Terril L; Smith, Philip H; Smith, Kathryn M Z et al. (2017) Guanfacine alters the effect of stress and smoking on heart rate variability in regular daily smokers. Psychopharmacology (Berl) 234:805-813
Weinberger, Andrea H; Pittman, Brian; Mazure, Carolyn M et al. (2015) A behavioral smoking treatment based on perceived risks of quitting: A preliminary feasibility and acceptability study with female smokers. Addict Res Theory 23:108-114
McKee, Sherry A; Potenza, Marc N; Kober, Hedy et al. (2015) A translational investigation targeting stress-reactivity and prefrontal cognitive control with guanfacine for smoking cessation. J Psychopharmacol 29:300-11
Udo, Tomoko; Weinberger, Andrea H; Grilo, Carlos M et al. (2014) Heightened vagal activity during high-calorie food presentation in obese compared with non-obese individuals--results of a pilot study. Obes Res Clin Pract 8:e201-98
Weinberger, Andrea H; Pilver, Corey E; Hoff, Rani A et al. (2013) Changes in smoking for adults with and without alcohol and drug use disorders: longitudinal evaluation in the US population. Am J Drug Alcohol Abuse 39:186-93
Weinberger, Andrea H; Pilver, Corey E; Desai, Rani A et al. (2013) The relationship of dysthymia, minor depression, and gender to changes in smoking for current and former smokers: longitudinal evaluation in the U.S. population. Drug Alcohol Depend 127:170-6
Udo, Tomoko; Grilo, Carlos M; Brownell, Kelly D et al. (2013) Modeling the effects of positive and negative mood on the ability to resist eating in obese and non-obese individuals. Eat Behav 14:40-6
McKee, Sherry A; Weinberger, Andrea H (2013) How can we use our knowledge of alcohol-tobacco interactions to reduce alcohol use? Annu Rev Clin Psychol 9:649-74
Ashare, Rebecca L; Sinha, Rajita; Lampert, Rachel et al. (2012) Blunted vagal reactivity predicts stress-precipitated tobacco smoking. Psychopharmacology (Berl) 220:259-68

Showing the most recent 10 out of 34 publications